THE LIFE SCIENCE INITIATIVE

TEL: +46 (0)18 57 23 53 , FAX: +46 (0)18 471 19 65
E-MAIL: MADELEINE.NEIL@UPPSALABIO.COM
WWW.UPPSALABIO.COM

PRESS RELEASE FROM UPPSALA BIO

Uppsala, 13 May 2004

Charles R. Cantor, Sequenom Inc., and Carl-Henrik Heldin, Ludwig Institute for Cancer Research, join Uppsala BIO-X Scientific Advisory Board

Uppsala BIO-X, the cross-disciplinary research effort within the overall Uppsala BIO initiative, has now appointed its scientific advisory board. Uppsala University and the Swedish University of Agricultural Sciences constitute the foundation of the effort, while life science industry actively supports the initiative.

- I am very much looking forward to participating in the construction of Uppsala BIO-X, says Charles R. Cantor, as I have a very positive view on how both research and the life science industry have developed in Sweden. Cross-disciplinary research is vital if we want to see more innovations within biotechnology, and it thus needs to be encouraged. I also hope that my engagement in Uppsala BIO-X will create new opportunities for research and business between Sweden and the US.

The role of the scientific advisory board is to advise on strategic issues and evaluate new and ongoing projects financed by Uppsala BIO-X with the goal of securing world-class research projects within its focus 'Tools for Life Science'.

- The combination of academic excellence and industrial know-how that we have achieved with this scientific advisory board is vital to the effort's ambition to create new academic knowledge and generate fresh opportunities for the life science industry, says Mr. Björn Ekström, Coordinator of Uppsala BIO-X.

Uppsala BIO-X Scientific Advisory Board will have its first meeting in Uppsala on May 26th. It consists of the following members:

Charles R. Cantor, Ph.D., Chief Scientific Officer of Sequenom Inc., San Diego, US. Dr. Cantor was previously Professor of Biomedical Engineering and Biophysics, and Director of the Center for Advanced Biotechnology at Boston University. Prior to that, he held positions at Columbia University and the University of California, Berkeley. Charles R. Cantor is a world-renowned scientist and is today a consultant to a large number of biotech companies around the world.

Carl-Henrik Heldin, Ph.D., Professor of Molecular Cell Biology at Uppsala University, and Director, Ludwig Institute for Cancer Research in Uppsala. Dr. Heldin serves on 12 academic and

commercial scientific advisory boards, is a member of the board of the Swedish Research Council and the Wallenberg Consortium North program in Functional Genomics. Dr. Heldin is also Senior Editor of Cancer Research, Associate Editor of Growth Factors, Molecular Biology of the Cell (formerly Cell Regulation) and Genes to Cells. He also serves on the editorial boards of several other international research publications.

Lars Rask, Ph.D., Professor of Medical Biochemistry, Uppsala University, and Dean, Faculty of Natural Resources and Agricultural Sciences, Swedish University of Agricultural Sciences (SLU).

Lars-Erik Nyström, Ph.D., Research Director at GE Healthcare, Uppsala, and formerly Director of Bioprocess Research, Amersham Biosciences. Dr. Nyström has more than 20 years experience from the biotechnological and biopharmaceutical industries both in Marketing and R&D.

Jon-Sverre Schanche, Ph.D., Vice President Research and Development, Biotage AB, Uppsala.

For further information, please contact:
Björn Ekström, Coordinator, Uppsala BIO-X, telephone +46 (0)70-655 41 10
Ingvar Wiberger, Senior Project Manager, Uppsala BIO, telephone +46 (0)70-346 57 37